Evommune, Inc. - EVMN
Ownership (Schedule 13D / 13G) · latest 50 filings
· Back to all files
Visible: 0
| Filed | Form | Reporting person | Percent | Shares | SEC |
|---|---|---|---|---|---|
| Aug 14, 2026 | SCHEDULE 13G/A | Andera Partners | 3.9% | 1,391,990 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | BioDiscovery 6 FPCI | 3.9% | 1,391,990 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Stephane Bergez | 3.9% | 1,391,990 | View |
| Aug 14, 2026 | SCHEDULE 13G/A | Francois Xavier Mauron | 3.9% | 1,391,990 | View |
| Aug 14, 2026 | SCHEDULE 13G | T. Rowe Price Associates, Inc. | 5.4% | 1,940,939 | View |
| Jul 16, 2026 | SCHEDULE 13G | Point72 Asset Management, L.P. | 5.3% | 1,910,489 | View |
| Jul 16, 2026 | SCHEDULE 13G | Point72 Capital Advisors, Inc. | 5.3% | 1,910,489 | View |
| Jul 16, 2026 | SCHEDULE 13G | Steven A. Cohen | 5.3% | 1,910,489 | View |
Percent = "% of class represented by amount beneficially owned" for this reporting person in the filed 13D/13G.
Shares = reported beneficial ownership amount for the same row (not portfolio shares from 13F).
Amendments (/A) can repeat the same holder over time, so rows should not be summed.
Extraction is best-effort from filing text and can be missing or noisy; verify exact figures via the SEC link in each row.